Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors

被引:88
|
作者
Santen, Richard J. [1 ]
Stuenkel, Cynthia A. [2 ]
Davis, Susan R. [3 ]
Pinkerton, Joann V. [4 ]
Gompel, Anne [5 ]
Lumsden, Mary Ann [6 ]
机构
[1] Univ Virginia Hlth Syst, Dept Internal Med, Charlottesville, VA 22903 USA
[2] Univ Calif San Diego, Div Endocrinol & Metab, La Jolla, CA 92093 USA
[3] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic 3004, Australia
[4] Univ Virginia Hlth Syst, Dept Obstet & Gynecol, Charlottesville, VA 22903 USA
[5] Paris Descartes Univ, Hop Univ Port Royal Cochin, Unite Gynecol Endocrinienne, F-75014 Paris, France
[6] Univ Glasgow, Sch Med, Dept Med Dent & Nursing, Glasgow G31 2ER, Lanark, Scotland
来源
关键词
QUALITY-OF-LIFE; HORMONE REPLACEMENT THERAPY; ESTROGEN-RECEPTOR MODULATORS; NOCTURNAL HOT FLASHES; VASOMOTOR SYMPTOMS; POSTMENOPAUSAL WOMEN; BAZEDOXIFENE/CONJUGATED ESTROGENS; AROMATASE INHIBITOR; GENITOURINARY SYNDROME; VITAMIN-D;
D O I
10.1210/jc.2017-01138
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Review evidence to guide management of menopausal signs and symptoms in women after breast cancer and make recommendations accordingly. Evidence: Randomized controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies. Background: Symptoms and clinical problems associated with estrogen depletion-sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis-confront the estimated 9.3 million breast cancer survivors globally. Recommendations: Following breast cancer, women should not generally be treated with menopausal hormone therapy or tibolone but should optimize lifestyle. Women with moderate to severe symptoms may benefit from mind-brain behavior or nonhormone, pharmacologic therapy. The selective serotonin/noradrenaline reuptake inhibitors and gabapentenoid agents improve VMS and quality of life. For osteoporosis, nonhormonal agents are available. Treatment of VVA remains an area of unmet need. Low-dose vaginal estrogen is absorbed in small amounts with blood levels remaining within the normal postmenopausal range but could potentially stimulate occult breast cancer cells, and although poorly studied, is not generally advised, particularly for those on aromatase inhibitors. Intravaginal dehydroepiandrosterone and oral ospemiphene have been approved to treat dyspareunia, but safety after breast cancer has not been established. Vaginal laser therapy is being used for VVA but efficacy from sham-controlled studies is lacking. Therapies undergoing development include lasofoxifene, neurokinin B inhibitors, stellate ganglion blockade, vaginal testosterone, and estetrol. Conclusions: Nonhormone options and therapies are available for treatment of estrogen depletion symptoms and clinical problems after a diagnosis of breast cancer. Individualization of treatment is essential.
引用
收藏
页码:3647 / 3661
页数:15
相关论文
共 50 条
  • [21] Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors
    Tran, Stephanie
    Hickey, Martha
    Saunders, Christobel
    Ramage, Lesley
    Cohen, Paul A.
    SUPPORTIVE CARE IN CANCER, 2021, 29 (03) : 1183 - 1193
  • [22] Effect of persistent menopausal symptoms on the wellbeing of Japanese breast cancer survivors
    Yamamoto, Sena
    Masutani, Eiko
    Arao, Harue
    NURSING & HEALTH SCIENCES, 2016, 18 (03) : 379 - 386
  • [23] Nonpharmacological therapies for the management of menopausal vasomotor symptoms in breast cancer survivors
    Stephanie Tran
    Martha Hickey
    Christobel Saunders
    Lesley Ramage
    Paul A. Cohen
    Supportive Care in Cancer, 2021, 29 : 1183 - 1193
  • [24] Somatosensory amplification and menopausal symptoms in breast cancer survivors and midlife women
    Carpenter, Janet S.
    Igega, Christele M.
    Otte, Julie L.
    Burns, Debra S.
    Yu, Menggang
    Wu, Jingwei
    MATURITAS, 2014, 78 (01) : 51 - 55
  • [25] Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women
    Asinaro, Giorgia
    Massarotti, Claudia
    Xholli, Anjeza
    Londero, Ambrogio P.
    Lambertini, Matteo
    Anserini, Paola
    Del Mastro, Lucia
    Cagnacci, Angelo
    MATURITAS, 2025, 191
  • [26] Managing menopausal symptoms after cancer
    Szabo, R. A.
    Marino, J. L.
    Hickey, M.
    CLIMACTERIC, 2019, 22 (06) : 572 - 578
  • [27] Homeopathy for menopausal symptoms in breast cancer survivors: A preliminary randomized controlled trial
    Jacobs, J
    Herman, P
    Heron, K
    Olsen, S
    Vaughters, L
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2005, 11 (01) : 21 - 27
  • [28] Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis
    Davis, Susan R.
    Panjari, Mary
    Robinson, Penelope J.
    Fradkin, Pamela
    Bell, Robin J.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2014, 21 (10): : 1075 - 1081
  • [29] The management of menopausal symptoms in breast cancer survivors: A case-based approach
    Lammerink, Ellen A. G.
    de Bock, Geertruida H.
    Schroder, Carolien P.
    Mourits, Marian J. E.
    MATURITAS, 2012, 73 (03) : 265 - 268
  • [30] Managing menopausal symptoms after gynecological cancer
    Michaelson-Cohen, Rachel
    Beller, Uziel
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (05) : 407 - 411